The Vision Council (TVC) has published a two-part research report, “Focused inSights 2025: Myopia Management,” which examines global pediatric myopia treatment strategies alongside a survey of U.S. eyecare providers. The report reviews treatment adoption, regulatory approvals, and prescribing practices across multiple regions, while also analyzing how U.S. clinicians approach diagnosis, management, and patient education.

“It’s clear from the survey that U.S. eyecare providers take myopia seriously, but they also face challenges in making care affordable and ensuring families understand the importance of treatment,” says TVC’s vice president of research and insights Alysse Henkel. “By also including an international analysis of treatment options and regulatory environments, this report offers a comprehensive view of where childhood myopia care stands today, and where it is headed.”

The first section, “Comparative Myopia Treatment Strategies,” compares regulatory environments and product availability in the U.S., Canada, the U.K., and the European Union. It covers four treatment categories: low-dose atropine drops, myopia control spectacle lenses, multifocal or dual-focus daily soft contact lenses, and orthokeratology. Key developments highlighted by TVC include the European Union’s approval of Ryjunea atropine drops and France’s reimbursement of myopia control spectacle lenses.

The second section, “Provider Approaches to Myopia Management Survey,” is based on responses from 293 optometrists, practice owners, and managers. Findings highlight how U.S. practices are implementing myopia management:

• Annual screenings are recommended by 91% of providers.

• Roughly 70% of practices report offering myopia management for children.

• CooperVision’s MiSight contact lenses are the most frequently prescribed treatment, cited by 81% of respondents.

• The main motivations for treatment include slowing the progression of myopia (78%), reducing complication risks (78%), and improving long-term eye health (71%).

• Excessive screen time and genetics are each identified as leading risk factors by 82% of providers, while limited outdoor activity is cited by 77%.

• Cost remains the most significant barrier (86%), followed by parental understanding (56%) and patient compliance (49%).

The full report is available here as a complimentary download for members and for nonmembers to purchase.